ALK boss on surprising bottom line: "The underlying operations are getting better and better"
Carste Hellmann, CEO of ALK, is excited about the company's financial report, where earnings in particular were a positive surprise. The difference between deficit and profit depends on how much the company spends on clinical trials from now on, he says.
There is good reason for celebrating at allergy company ALK, after the company released a financial report on Thursday morning which positively surprised analysts and sent share prices up by 6 percent. CEO Carsten Hellmann explains the excitement to MedWatch:
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
.jpg&w=384&q=75){kind=logo}
